https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-62015-02-16 00:00:002019-02-15 08:45:38Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-11 / Cancer Res. 2015 Apr;75(7):1265-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-11 / Cancer Res. 2015 Apr;75(7):1265-742015-02-11 00:00:002019-02-15 08:53:32Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor β
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-29 / Oncol. Rep. 2015 Apr;33(4):1585-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-29 / Oncol. Rep. 2015 Apr;33(4):1585-922015-01-29 00:00:002019-02-15 08:52:44A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-23 / Int. J. Oncol. 2015 Apr;46(4):1699-709
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-23 / Int. J. Oncol. 2015 Apr;46(4):1699-7092015-01-23 00:00:002019-02-15 08:52:05Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-22 / Br. J. Haematol. 2015 May;169(3):356-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-22 / Br. J. Haematol. 2015 May;169(3):356-672015-01-22 00:00:002019-02-15 08:45:29Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-07 / Urol. Oncol. 2015 May;33(5):245-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-07 / Urol. Oncol. 2015 May;33(5):245-602015-01-07 00:00:002019-02-15 08:53:08Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-02 / Expert Opin Biol Ther 2015 Apr;15(4):569-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-02 / Expert Opin Biol Ther 2015 Apr;15(4):569-822015-01-02 00:00:002019-02-15 08:39:35Potential approaches for more successful dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-01 / Cancer Treat. Res. 2015;163:143-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-01 / Cancer Treat. Res. 2015;163:143-582015-01-01 00:00:002019-02-15 08:46:19Immunotherapy for malignant gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-01 / Anticancer Res. 2015 Jan;35(1):555-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-01 / Anticancer Res. 2015 Jan;35(1):555-622015-01-01 00:00:002019-02-15 08:52:28Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-12-11 / Hepat Oncol 2014 Oct;1(4):433-446
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-12-11 / Hepat Oncol 2014 Oct;1(4):433-4462014-12-11 00:00:002014-12-11 00:00:00Immunotherapy of hepatocellular carcinoma
